Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2012 May 7;18(17):2061-6. doi: 10.3748/wjg.v18.i17.2061.

Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Author information

  • 1Department of Surgery, University of Tübingen, Hoppe-Seyler-Strasse 3, D-72076 Tübingen, Germany. ingmar.koenigsrainer@med.uni-tuebingen.de

Abstract

AIM:

To investigate perioperative patient morbidity/mortality and outcome after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

METHODS:

Of 150 patients 100 were treated with cytoreductive surgery and HIPEC and retrospectively analyzed. Clinical and postoperative follow-up data were evaluated. Body mass index (BMI), age and peritoneal carcinomatosis index (PCI) were chosen as selection criteria with regard to tumor-free survival and perioperative morbidity for this multimodal therapy.

RESULTS:

CRS with HIPEC was successfully performed in 100 out of 150 patients. Fifty patients were excluded because of intraoperative contraindication. Median PCI was 17 (1-39). In 89% a radical resection (CC0/CC1) was achieved. One patient died postoperatively due to multiorgan failure. Neither PCI, age nor BMI was a risk factor for postoperative complications/outcome according to the DINDO classification. In 9% Re-CRS with HIPEC was performed during the follow-up period.

CONCLUSION:

Patient selection remains the most important issue. Neither PCI, age nor BMI alone should be an exclusion criterion for this multimodal therapy.

KEYWORDS:

Complications; Hyperthermic intraoperative chemotherapy; Peritoneal carcinomatosis; Risk assessment; Selection criteria; Single-center experience

PMID:
22563193
[PubMed - indexed for MEDLINE]
PMCID:
PMC3342604
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk